Data updated: May 26, 2026
ZIRABEV (bevacizumab-bvzr)
Vascular Endothelial Growth Factor-directed Antibody Interactions Genetically Validated
Oncology
Approved 2019-06-27
ZIRABEV is indicated for the treatment of Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Renal Cell Carcinoma; Cervical Cancer; Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer.
How ZIRABEV Works
ZIRABEV functions by binding to vascular endothelial growth factor (VEGF), preventing it from interacting with its receptors, Flt-1 and KDR, on the surface of endothelial cells. Under normal conditions, the interaction of VEGF with these receptors triggers endothelial cell proliferation and the formation of new blood vessels, a process called angiogenesis. By blocking this interaction, the drug inhibits the development of new microvascular growth. This mechanism serves to limit the blood supply to tumors and inhibit the progression of metastatic disease.
2
Indications
--
Phase 3 Trials
6
Years on Market
Details
- Status
- Prescription
- First Approved
- 2019-06-27
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
ZIRABEV Approval History
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
10 FDA actions from 2019 to 2024
What ZIRABEV Treats
8 indicationsZIRABEV is approved for 8 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Metastatic Colorectal Cancer
- Non-Small Cell Lung Cancer
- Glioblastoma
- Renal Cell Carcinoma
- Cervical Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
Source: FDA Label
ZIRABEV Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
VEGFR (Vascular Endothelial Growth Factor Receptor) receptor
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
ZIRABEV is a lower-cost alternative to Avastin with no clinically meaningful differences. Requires prescriber approval to substitute.
ZIRABEV Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
6
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
10
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
10
Same indication, different mechanism — what else might this patient receive?
Unlock 20 more competitors across all three rings.
Upgrade to Pro Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in ZIRABEV's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications ZIRABEV treats. First-in-class if their pivotal trials read out positive.
Tiragolumab MTIG7192A / RG6058 ~ Mixed — Ph3 readout
Hoffmann-La Roche TIGIT · monoclonal antibody (anti-TIGIT) · 10 Phase 3 trials
Ceralasertib AZD6738 ~ Mixed — Ph3 readout
AstraZeneca ATR · small-molecule ATR kinase inhibitor · 2 Phase 3 trials
Brigimadlin BI 907828
Boehringer Ingelheim MDM2 · small-molecule MDM2-p53 inhibitor · 3 Phase 3 trials
Uliledlimab TJ004309
TJ Biopharma Co., Ltd. NT5E · monoclonal antibody (anti-CD73) · 1 Phase 3 trial
Drugs Similar to ZIRABEV
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
📋
Clinical Trial Registry
1058 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05005403 | M21-410 | Ph 1 | recruiting | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan |
| NCT04181060 | NCI-2019-07941 NCI-2019-07941, EA5182 | Ph 3 | recruiting | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer |
| NCT07012798 | DB-HERO | Ph 2 | recruiting | FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma |
| NCT06787612 | R4018-ONC-2445 2024-517806-27-00 | Ph 2 | recruiting | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer |
| NCT07198074 | NCI-2025-06974 NCI-2025-06974, NRG-GY035 | Ph 3 | recruiting | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer |
| NCT03141684 | NCI-2016-01040 NCI-2016-01040, CC 17-C-0074 | Ph 2 | active not recruiting | Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma |
| NCT05211323 | NCI-2022-00151 NCI-2022-00151, EA2205 | Ph 2 | active not recruiting | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer |
| NCT04981509 | NCI-2021-07744 NCI-2021-07744, 22-C-0004 | Ph 2 | recruiting | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer |
| NCT06696768 | NCI-2024-09416 NCI-2024-09416, 10655 | Ph 1 | recruiting | Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer |
| NCT07504588 | NCI-2026-01998 NCI-2026-01998, NRG-GY038 | Ph 2 | not yet recruiting | Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy |
| NCT05063552 | NCI-2021-10021 NCI-2021-10021, EA3202 | Ph 2, Ph 3 | active not recruiting | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers |
| NCT06843447 | 5909-003 MK-5909-003, 2024-514674-47-00 | Ph 1, Ph 2 | recruiting | A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) |
| NCT02997228 | NCI-2016-01961 NCI-2016-01961, NRG-GI004/S1610 | Ph 3 | active not recruiting | Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study |
| NCT06890338 | M25-231 GOG-3115 | Ph 2 | recruiting | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. |
| NCT05001880 | NCI-2021-08573 NCI-2021-08573, A092001 | Ph 2 | recruiting | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma |
| NCT03337698 Morpheus Lung results posted | BO39610 2017-001267-21 | Ph 1, Ph 2 | terminated | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) |
| NCT05862285 UmbrellaMAX | BX44273 2022-003414-36, 2023-504263-16-00 | Ph 3 | recruiting | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study |
| NCT04245085 ABC-lung results posted | ETOP 15-19 MO40586 | Ph 2 | completed | ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma |
| NCT05919264 | FOG-001-101 | Ph 1, Ph 2 | recruiting | FOG-001 in Locally Advanced or Metastatic Solid Tumors |
| NCT02308527 BEACON | RG_11-087 2012-000072-42 | Ph 2 | completed | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children |
| NCT07448922 | SKB518-II-03 | Ph 2 | recruiting | A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors |
| NCT05647122 EGRET | D9350C00001 2022-501570-18-00 | Ph 1 | recruiting | First in Human Study of AZD9592 in Solid Tumors |
| NCT06271837 | D781AC00001 | Ph 2 | active not recruiting | A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors |
| NCT06792695 CANTOR | D798VC00001 2024-518469-84 | Ph 2 | recruiting | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer |
| NCT06921785 ARTEMIDE-HCC01 | D7029C00001 | Ph 3 | recruiting | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma |
| NCT06004245 | VVD-133214-01 2023-503170-20-01 | Ph 1 | recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors |
| NCT07318558 TroFuse-021 | 2870-021 MK-2870-021, GOG-3102 | Ph 3 | recruiting | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) |
| NCT06824467 | 2870-022 MK-2870-022, TroFuse-022 | Ph 3 | recruiting | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) |
| NCT06663319 | 89402638GIC1001 2024-516526-66-00 | Ph 1 | recruiting | A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers |
| NCT00959647 results posted | SHH4437g GO01352 | Ph 2 | completed | A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study |
| NCT07318805 | C6321001 2025-524387-38-00 | Ph 1 | recruiting | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors |
| NCT07216703 | 2870-036 U1111-1319-9926, 2025-521514-26-00 | Ph 3 | recruiting | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) |
| NCT07549412 | MS914001_0002 2025-524648-37-00 | Ph 3 | recruiting | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) |
| NCT07291076 | CA266-0006 2025-523602-33, U1111-1327-4912 | Ph 1, Ph 2 | recruiting | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) |
| NCT06750094 OrigAMI-3 | 61186372COR3002 2024-513853-66-00 | Ph 3 | recruiting | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy |
| NCT07284849 | INCA033890-303 2025-523735-19-00 | Ph 3 | recruiting | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer |
| NCT05797246 | 10001572 001572-C | Ph 2 | active not recruiting | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) |
| NCT06023862 DOVE | 4-2023-0794 | Ph 2 | recruiting | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) |
| NCT07557251 | BRII-5395-001 | Ph 1 | not yet recruiting | A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma |
| NCT04374305 INTUITT-NF2 | 19-828 | Ph 2 | recruiting | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) |
| NCT07221357 | CA266-0003 2025-523224-45, U1111-1325-6505 | Ph 2, Ph 3 | recruiting | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer |
| NCT05863195 | EA2222 NCI-2023-02357, EA2222 | Ph 3 | recruiting | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial |
| NCT07225270 RAINFOL-04 | GCT1184-04 2025-522167-15-00, jRCT2051250197 | Ph 3 | recruiting | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy |
| NCT07503756 | JS212-005-II-CRC | Ph 2 | recruiting | JS212 Combination Therapies in Metastatic Colorectal Cancer |
| NCT05083481 | 1570-CL-0101 jRCT2031220527, KEYNOTE-E59 | Ph 1, Ph 2 | active not recruiting | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors |
| NCT07446322 | REO 033 | Ph 2 | recruiting | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer |
| NCT01167712 results posted | NCI-2011-03812 NCI-2011-03812, GOG-0262/ACRIN 6695 | Ph 3 | active not recruiting | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT07166406 | NRG-GI012 NCI-2025-05951, NRG-GI012 | Ph 3 | recruiting | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial |
| NCT03740165 results posted | 7339-001 ENGOT-ov43, MK-7339-001 | Ph 3 | completed | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) |
| NCT06618664 | SHR-8068-301 | Ph 3 | recruiting | A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma |
Showing 50 of 1058 trials
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ZIRABEV FDA Label Details
Indications & Usage
FDA Label (PDF)ZIRABEV is indicated for the treatment of Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Renal Cell Carcinoma; Cervical Cancer; Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer.
Track ZIRABEV with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.